424B3 1 ss62174_424b3-biotech.htm

PROSPECTUS SUPPLEMENT
 
REGISTRATION NO.  333-89355
(To Prospectus dated March 11, 2009)
 
Filed Pursuant to Rule 424(b)(3)
 
 
 
 

 
1,000,000,000 Depositary Receipts
Biotech HOLDRS (SM) Trust
 
This prospectus supplement supplements information contained in the prospectus dated March 11, 2009 relating to the sale of up to 1,000,000,000 depositary receipts by the Biotech HOLDRS (SM) Trust.
 
The share amounts specified in the table in the “Highlights of Biotech HOLDRS” section of the base prospectus shall be replaced with the following:
 
Name of Company1
 
Ticker
 
Share
Amounts
 
Primary
Trading
Market
Affymetrix, Inc.
 
AFFX
 
4.0000
 
NASDAQ
Alkermes, Inc.
 
ALKS
 
4.0000
 
NASDAQ
Amgen Inc.
 
AMGN
 
64.4800
 
NASDAQ
Biogen IDEC Inc.
 
BIIB
 
26.9500
 
NASDAQ
Celera Corporation
 
CRA
 
4.0000
 
NASDAQ
Enzon Pharmaceuticals, Inc.
 
ENZN
 
3.0000
 
NASDAQ
Genzyme Corporation
 
GENZ
 
14.0000
 
NASDAQ
Gilead Sciences, Inc.
 
GILD
 
64.0000
 
NASDAQ
Human Genome Sciences, Inc.
 
HGSI
 
8.0000
 
NASDAQ
Life Technologies Corporation
 
LIFE
 
8.1774
 
NASDAQ
QLT Inc.
 
QLTI
 
5.0000
 
NASDAQ
Sepracor Inc.
 
SEPR
 
6.0000
 
NASDAQ
Shire plc
 
SHPGY
 
6.8271
 
NASDAQ

The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.

The date of this prospectus supplement is April 29, 2009.